Autoimune Thyroiditis and Diabetes Mellitus Type 1 after Long-term Gonadotropin-releasing Hormone Agonist Treatment for Central Precocious Puberty: Evolution or Coincidence?

Author(s):  
Marina Krstevska-Konstantinova ◽  
Aleksandra Jancevska ◽  
Zoran Gucev
2020 ◽  
Vol 12 (1) ◽  
pp. 62-65
Author(s):  
Maja Tankoska ◽  
Avdi Murtezani ◽  
Konstandina Kuzevska-Maneva ◽  
Marina Krstevska – Konstantinova

There is a small number of studies that have reported abnormalities in endocrine function after a long-term gonadotropin-releasing hormone agonist (GnRHa) treatment in girls. This treatment is considered as safe and effective by most authors. We report our second case of unusual outcome of long-term GnRHa therapy in a girl with central precocious puberty (CPP) of idiopathic or familial etiology. She has received monthly depot of injections of triptorelin for a time period of 4 years. We have examined thyroid function by measuring serum levels of thyrotropin (TSH), thyroxine (T4), thyroid antibodies and ultrasound of thyroid gland. At the age of 11 years she developed a mild goiter and presented with autoimmune thyroiditis, having elevated thyroid antibodies and ultrasound of thyroid gland typical for Hashimoto thyroiditis. Having in mind these two cases, we suggest a closer monitoring of thyroid function in girls with CPP, before and during therapy with GnRH agonist.


Sign in / Sign up

Export Citation Format

Share Document